ATE490466T1 - Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen - Google Patents

Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen

Info

Publication number
ATE490466T1
ATE490466T1 AT02739098T AT02739098T ATE490466T1 AT E490466 T1 ATE490466 T1 AT E490466T1 AT 02739098 T AT02739098 T AT 02739098T AT 02739098 T AT02739098 T AT 02739098T AT E490466 T1 ATE490466 T1 AT E490466T1
Authority
AT
Austria
Prior art keywords
cells
tests
functional control
internal functional
detecting rare
Prior art date
Application number
AT02739098T
Other languages
English (en)
Inventor
Leon Terstappen
Galla Rao
Herman Rutner
Paul Liberti
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc filed Critical Veridex Llc
Application granted granted Critical
Publication of ATE490466T1 publication Critical patent/ATE490466T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C1/00—Magnetic separation
    • B03C1/005—Pretreatment specially adapted for magnetic separation
    • B03C1/01—Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02739098T 2001-03-07 2002-03-07 Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen ATE490466T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/801,471 US20010018192A1 (en) 1998-02-12 2001-03-07 Labeled cells for use as an internal functional control in rare cell detection assays
PCT/US2002/006967 WO2002077604A2 (en) 2001-03-07 2002-03-07 Labeled cells for use as an internal functional control in rare cell detection assays

Publications (1)

Publication Number Publication Date
ATE490466T1 true ATE490466T1 (de) 2010-12-15

Family

ID=25181182

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02739098T ATE490466T1 (de) 2001-03-07 2002-03-07 Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen

Country Status (10)

Country Link
US (1) US20010018192A1 (de)
EP (2) EP2280283B1 (de)
JP (1) JP2004534210A (de)
AT (1) ATE490466T1 (de)
AU (1) AU2002311773A1 (de)
DE (1) DE60238493D1 (de)
DK (1) DK2280283T3 (de)
ES (2) ES2527210T3 (de)
PT (1) PT2280283E (de)
WO (1) WO2002077604A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282350B2 (en) 1998-02-12 2007-10-16 Immunivest Corporation Labeled cell sets for use as functional controls in rare cell detection assays
CA2350692A1 (en) * 1998-10-29 2000-05-11 Cell Works Diagnostics, Inc. Multiple marker characterization of single cells
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
EP1481248A2 (de) * 2002-03-01 2004-12-01 Cardiff & Vale National Health service Trust Universitiy Hospital of Wales Verfahren zur bestimmung der zellzahl
EP2359689B1 (de) 2002-09-27 2015-08-26 The General Hospital Corporation Mikrofluid-Vorrichtung zur Zelltrennung, sowie Verwendung derselben
CA2445204C (en) 2002-10-16 2014-08-12 Streck Laboratories, Inc. Method and device for collecting and preserving cells for analysis
CA2516795C (en) 2003-02-27 2013-01-15 Immunivest Corporation Circulating tumor cells (ctc's): early assessment of time to progression,_survival and response to therapy in metastatic cancer patients
CA2539108A1 (en) * 2003-09-18 2005-03-31 Immunivest Corporation Operator independent programmable sample preparation and analysis system
WO2005030995A1 (en) * 2003-09-23 2005-04-07 University Of Missouri Methods of synthesizing polynucleotides using thermostable enzymes
US20050181353A1 (en) * 2004-02-17 2005-08-18 Rao Galla C. Stabilization of cells and biological specimens for analysis
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070128668A1 (en) * 2005-12-01 2007-06-07 Larry Burg Quantitative use of tracer cells
US8337755B2 (en) 2006-03-13 2012-12-25 Veridex, Llc Operator independent programmable sample preparation and analysis system
NZ573187A (en) * 2006-06-02 2011-11-25 Pfizer Prod Inc Circulating tumor cell assay for predicting efficacy of 1gf-1r antagonist therapy
EP2041299A4 (de) 2006-07-14 2010-01-13 Aviva Biosciences Corp Verfahren und zusammensetzungen für den nachweis seltener zellen aus einer biologischen probe
US7828968B2 (en) 2007-08-30 2010-11-09 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
US8110101B2 (en) 2007-08-30 2012-02-07 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
EP2225563B1 (de) * 2007-11-27 2015-01-21 Janssen Diagnostics, LLC Automatische zählung und charakterisierung von im blut zirkulierenden melanomzellen
EP2359164A4 (de) 2008-12-10 2012-05-30 Abqmr Inc Kernmagnetresonanzgerät, verfahren und zugehörige technologie
US11634747B2 (en) * 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
NO2398912T3 (de) 2009-02-18 2018-02-10
US20110111410A1 (en) * 2009-11-09 2011-05-12 Streck, Inc. Stabilization of rna in intact cells within a blood sample
US20110262989A1 (en) 2010-04-21 2011-10-27 Nanomr, Inc. Isolating a target analyte from a body fluid
US9428547B2 (en) 2010-04-21 2016-08-30 Dna Electronics, Inc. Compositions for isolating a target analyte from a heterogeneous sample
US8841104B2 (en) 2010-04-21 2014-09-23 Nanomr, Inc. Methods for isolating a target analyte from a heterogeneous sample
US9476812B2 (en) 2010-04-21 2016-10-25 Dna Electronics, Inc. Methods for isolating a target analyte from a heterogeneous sample
EP2657346B1 (de) 2010-12-24 2017-08-23 ARKRAY, Inc. Verfahren für den nachweis von krebszellen
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
WO2013036620A1 (en) * 2011-09-06 2013-03-14 Becton, Dickinson And Company Methods and compositions for cytometric detection of rare target cells in a sample
US20150056649A1 (en) 2012-01-13 2015-02-26 Konica Minolta, Inc. Method for quantifying cell of interest in blood, and method for evaluating system for quantifying said cell
CN104981236B (zh) * 2012-09-27 2019-01-22 珠海圣美生物诊断技术有限公司 刺激敏感性微粒和使用方法
CA2885845C (en) * 2012-11-07 2019-10-29 Sandstone Diagnostics, Inc. Methods and devices for processing samples and counting cells
US9995742B2 (en) 2012-12-19 2018-06-12 Dnae Group Holdings Limited Sample entry
US9804069B2 (en) 2012-12-19 2017-10-31 Dnae Group Holdings Limited Methods for degrading nucleic acid
US9551704B2 (en) 2012-12-19 2017-01-24 Dna Electronics, Inc. Target detection
US10000557B2 (en) 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
US9434940B2 (en) 2012-12-19 2016-09-06 Dna Electronics, Inc. Methods for universal target capture
US9599610B2 (en) 2012-12-19 2017-03-21 Dnae Group Holdings Limited Target capture system
WO2014124179A1 (en) 2013-02-07 2014-08-14 Sandstone Diagnostics, Inc. Automated sample processing, fluid distribution, and sedimentation assay
US20150233932A1 (en) * 2013-02-19 2015-08-20 Ching-Ping Tseng Methods, Systems, and Compositions for Enrichment of Rare Cells
US10091984B2 (en) 2013-07-24 2018-10-09 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
WO2015017535A2 (en) * 2013-08-02 2015-02-05 Siemens Healthcare Diagnostics Inc. Cell-based control and method
JP6331524B2 (ja) * 2014-03-14 2018-05-30 日立化成株式会社 標準細胞液
CN104568923A (zh) * 2014-12-01 2015-04-29 浙江省肿瘤医院 电化学发光检测外周血循环肿瘤细胞抗原的方法及试剂盒
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
JP6582486B2 (ja) * 2015-03-27 2019-10-02 コニカミノルタ株式会社 血液中の稀少細胞検出方法
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
WO2018022991A1 (en) 2016-07-29 2018-02-01 Streck, Inc. Suspension composition for hematology analysis control
CN115119829B (zh) 2017-10-19 2024-07-12 斯特雷克股份有限公司 用于胞外囊泡的溶血和凝血调节以及稳定化的组合物
JP6485576B2 (ja) * 2018-04-19 2019-03-20 日立化成株式会社 標準細胞液
US20220175926A1 (en) * 2019-03-29 2022-06-09 The Brigham And Women's Hospital, Inc. Targeted synergistic cancer immunotherapy
US12306177B2 (en) * 2020-05-13 2025-05-20 Becton, Dickinson And Company Blood based controls for complex panel

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5188935A (en) * 1984-05-31 1993-02-23 Coulter Electronics, Inc. Reagent system and method for identification, enumeration and examination of classes and subclasses of blood leukocytes
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5597531A (en) * 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
US5187099A (en) * 1986-10-29 1993-02-16 Coulter Corporation Control slide for immunoassay kit using a low-temperature melting paraffin
JP2619911B2 (ja) 1988-04-08 1997-06-11 東亜医用電子株式会社 網状赤血球測定装置用標準血液
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
US5698271A (en) * 1989-08-22 1997-12-16 Immunivest Corporation Methods for the manufacture of magnetically responsive particles
US5610022A (en) * 1989-09-26 1997-03-11 City Of Hope Internal control for immunocytochemistry assay
IE76319B1 (en) 1990-07-23 1997-10-22 Becton Dickinson Co Preservation of cells as controls or standards in cellular analysis
US5478722A (en) * 1991-02-17 1995-12-26 The Curators Of The University Of Missouri Preserved cell preparations for flow cytometry and immunology
US5270208A (en) * 1991-05-09 1993-12-14 Streck Laboratories, Inc. White blood cell hematology control
EP0628166B1 (de) * 1992-02-24 2000-05-31 Coulter Corporation Suspensionsmedien für hämatoligische zusammensetzungen und methode für ihren gebrauch
WO1993018397A1 (en) * 1992-03-02 1993-09-16 Streck Laboratories, Inc. Reference control for use with manual and flow cytometric reticulocyte counting devices
US5763204A (en) * 1992-09-14 1998-06-09 Coulter Corporation Preparation of preserved, non-infectious control cell for use in the identification of a disease through blood testing
US5342754A (en) * 1992-09-14 1994-08-30 Coulter Corporation Preserved, non-infectious control cell for use in the identification of a disease through blood testing
AU6024294A (en) 1993-01-08 1994-08-15 Coulter Corporation Method of using preserved control cells in the calibration of fluorescent and light scatter measurements
EP0608987B1 (de) * 1993-01-26 2001-10-10 Becton, Dickinson and Company Verfahren zum Nachweis von seltenen Ereignissen
US5629933A (en) * 1995-06-07 1997-05-13 International Business Machines Corporation Method and system for enhanced communication in a multisession packet based communication system
JP3875754B2 (ja) * 1995-11-17 2007-01-31 シスメックス株式会社 フローサイトメータ用標準液
JP3996644B2 (ja) * 1996-06-07 2007-10-24 イムニベスト・コーポレイション 外部及び内部勾配を有する磁気分離
US5968831A (en) * 1996-10-29 1999-10-19 Coulter International Corp. Cell control used to confirm enzymatic activity
WO2000002049A1 (en) * 1998-07-01 2000-01-13 Nitto Denko Corporation Immunologic test method and immunologic test kit
ES2274781T3 (es) 1999-04-13 2007-06-01 Wilex Ag Empleo diagnostico y terapeutico de anticuerpos contra el receptor de la urocinasa.
GB0022017D0 (en) * 2000-09-08 2000-10-25 Univ Dundee Cell assays

Also Published As

Publication number Publication date
EP1429603A4 (de) 2004-08-18
AU2002311773A1 (en) 2002-10-08
DE60238493D1 (de) 2011-01-13
PT2280283E (pt) 2015-02-03
WO2002077604A3 (en) 2004-04-01
US20010018192A1 (en) 2001-08-30
ES2357101T3 (es) 2011-04-18
DK2280283T3 (en) 2014-11-17
EP1429603B1 (de) 2010-12-01
JP2004534210A (ja) 2004-11-11
EP2280283A1 (de) 2011-02-02
EP2280283B1 (de) 2014-10-15
WO2002077604A2 (en) 2002-10-03
HK1152378A1 (en) 2012-02-24
ES2527210T3 (es) 2015-01-21
EP1429603A2 (de) 2004-06-23

Similar Documents

Publication Publication Date Title
ATE490466T1 (de) Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen
BR0107574A (pt) Métodos e kits para identificar evento de elite gat-zm1 em amostras biológicas
BRPI0002963B1 (pt) processo e dispositivo medidor eletroquìmico para medir uma concentração de analito em uma amostra.
AU2002341621A1 (en) Methods, reagents, kits and apparatus for protein function analysis
WO2004074310A3 (en) Mycobacterial diagnostics
BR0112385A (pt) Meio de coleta universal
EP1687283A4 (de) Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung
WO2005018418A3 (en) Automated quality control protocols in a multi-analyser system
EP1373567A4 (de) "nachweis von sequenzen, die reich an methyliertem cpg sind, zur diagnose maligner zellen"
ATE354679T1 (de) Diagnosesysteme auf basis von kulturen gemischter zellen
AU2002364120A1 (en) Sensor for the use in testing biological chemical or environmental samples
AU2003229455A1 (en) Rapid vaccinia antibody detection device, method and test kit
IL172895A0 (en) Device, kit and method for pulsing biological samples with an agent and stabilising the sample so pulsed
WO2007086900A3 (en) Stilbazium research assays
DE60139056D1 (de) Blutzellen-Detektor, Blutanalysegerät und Blutanalyseverfahren unter Verwendung des Detektors
ATE365908T1 (de) Vorrichtung und verfahren zur entnahme von proben
WO2004010143A3 (en) Electrochemical lateral flow and flow-through devices
ATE504833T1 (de) Verfahren zur bestimmung des phänotyps von zellen
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
WO2002066982A8 (de) Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer)
ATE340998T1 (de) Verfahren zur bestimmung von flüchtigen substanzen in lösung
WO2001062953A3 (fr) Procede electrochimique de detection d'acides nucleiques
AU1021901A (en) Electrophoresis device for analysing labelled molecules, in particular, biological molecules
EP2400029A3 (de) Verfahren zur zyklischen Nukleotidbestimmung
WO2002064756A3 (en) Stem cell identification

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1429603

Country of ref document: EP